Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MDGL |
---|---|---|
09:32 ET | 1309 | 206.79 |
09:34 ET | 200 | 208.39 |
09:36 ET | 400 | 208.47 |
09:43 ET | 169 | 209.68 |
09:50 ET | 542 | 208.535 |
09:52 ET | 100 | 208.515 |
09:56 ET | 200 | 208.485 |
09:57 ET | 239 | 208.59 |
10:01 ET | 100 | 208.19 |
10:03 ET | 267 | 209.82 |
10:08 ET | 100 | 209.98 |
10:10 ET | 574 | 208.5402 |
10:12 ET | 100 | 210.16 |
10:14 ET | 100 | 211.28 |
10:15 ET | 100 | 211.06 |
10:17 ET | 4380 | 211.62 |
10:21 ET | 100 | 211.96 |
10:24 ET | 100 | 210.94 |
10:26 ET | 100 | 210.565 |
10:28 ET | 200 | 210.8517 |
10:30 ET | 100 | 211.18 |
10:35 ET | 1360 | 211.37 |
10:37 ET | 100 | 211.71 |
10:39 ET | 300 | 211.37 |
10:42 ET | 496 | 212.035 |
10:46 ET | 300 | 212.565 |
10:48 ET | 100 | 212.725 |
10:51 ET | 1100 | 212.17 |
10:55 ET | 484 | 211.6793 |
11:02 ET | 100 | 210.41 |
11:04 ET | 123 | 211.33 |
11:06 ET | 420 | 211.58 |
11:08 ET | 100 | 212.05 |
11:13 ET | 425 | 211.01 |
11:24 ET | 200 | 211.145 |
11:26 ET | 100 | 210.95 |
11:27 ET | 100 | 210.945 |
11:36 ET | 100 | 210.86 |
11:40 ET | 500 | 211.67 |
11:42 ET | 5503 | 212.1 |
11:44 ET | 100 | 212.045 |
11:45 ET | 500 | 212.35 |
11:47 ET | 350 | 212.005 |
11:49 ET | 500 | 211.935 |
11:51 ET | 200 | 211.575 |
11:54 ET | 900 | 211.3 |
11:56 ET | 400 | 211.31 |
11:58 ET | 400 | 211.055 |
12:00 ET | 100 | 211.055 |
12:02 ET | 100 | 211.34 |
12:05 ET | 300 | 211.33 |
12:07 ET | 100 | 211.26 |
12:12 ET | 100 | 211.41 |
12:14 ET | 200 | 211.22 |
12:16 ET | 200 | 211.42 |
12:18 ET | 100 | 211.52 |
12:21 ET | 500 | 210.89 |
12:23 ET | 100 | 210.59 |
12:27 ET | 1900 | 210.22 |
12:30 ET | 1280 | 210.51 |
12:32 ET | 300 | 210.51 |
12:36 ET | 100 | 209.92 |
12:38 ET | 200 | 209.8 |
12:52 ET | 300 | 209.755 |
12:56 ET | 100 | 209.7 |
12:57 ET | 900 | 209.54 |
01:01 ET | 100 | 209.31 |
01:06 ET | 100 | 208.89 |
01:08 ET | 100 | 209.125 |
01:10 ET | 100 | 209.115 |
01:12 ET | 400 | 208.665 |
01:15 ET | 1600 | 207.8 |
01:17 ET | 200 | 208.24 |
01:19 ET | 781 | 208.06 |
01:24 ET | 325 | 208.05 |
01:26 ET | 400 | 207.51 |
01:28 ET | 200 | 207.8 |
01:30 ET | 2400 | 208.485 |
01:32 ET | 200 | 208.69 |
01:33 ET | 267 | 208.495 |
01:39 ET | 400 | 209.08 |
01:46 ET | 200 | 209.815 |
01:50 ET | 400 | 210.235 |
01:57 ET | 4700 | 210.24 |
02:04 ET | 250 | 210.6158 |
02:06 ET | 650 | 210.53 |
02:08 ET | 600 | 210.32 |
02:09 ET | 225 | 210.245 |
02:11 ET | 100 | 210.155 |
02:13 ET | 200 | 210.46 |
02:24 ET | 100 | 210.88 |
02:29 ET | 400 | 210.36 |
02:31 ET | 100 | 210.535 |
02:33 ET | 300 | 210.575 |
02:36 ET | 300 | 210.57 |
02:47 ET | 100 | 210.44 |
02:49 ET | 600 | 210.62 |
02:51 ET | 100 | 210.615 |
02:54 ET | 300 | 210.22 |
02:56 ET | 200 | 210.05 |
02:58 ET | 200 | 210.08 |
03:03 ET | 100 | 209.94 |
03:05 ET | 600 | 210.08 |
03:07 ET | 400 | 209.99 |
03:09 ET | 200 | 209.805 |
03:12 ET | 400 | 209.625 |
03:14 ET | 500 | 209.54 |
03:18 ET | 400 | 209.5 |
03:20 ET | 100 | 209.63 |
03:21 ET | 300 | 209.32 |
03:23 ET | 200 | 209.63 |
03:25 ET | 896 | 208.96 |
03:27 ET | 775 | 208.975 |
03:32 ET | 500 | 208.985 |
03:34 ET | 780 | 208.72 |
03:36 ET | 800 | 209.02 |
03:38 ET | 400 | 209.075 |
03:39 ET | 1400 | 208.98 |
03:41 ET | 1876 | 208.97 |
03:43 ET | 300 | 208.64 |
03:45 ET | 500 | 208.74 |
03:48 ET | 1055 | 208.58 |
03:50 ET | 1401 | 208.89 |
03:52 ET | 500 | 209.175 |
03:54 ET | 1033 | 208.97 |
03:56 ET | 1300 | 208.95 |
03:57 ET | 1893 | 208.96 |
03:59 ET | 25324 | 209.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Madrigal Pharmaceuticals Inc | 4.5B | -8.2x | --- |
Biohaven Ltd | 4.7B | -5.2x | --- |
Immunovant Inc | 4.3B | -15.4x | --- |
BridgeBio Pharma Inc | 4.7B | -9.5x | --- |
Crinetics Pharmaceuticals Inc | 4.3B | -14.3x | --- |
Krystal Biotech Inc | 5.1B | 48.6x | --- |
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.5B |
---|---|
Revenue (TTM) | $14.6M |
Shares Outstanding | 21.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.44 |
EPS | $-25.50 |
Book Value | $20.39 |
P/E Ratio | -8.2x |
Price/Sales (TTM) | 310.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,622.65% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.